Picture of Sartorius Stedim Biotech SA logo

DIM — Sartorius Stedim Biotech SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Sartorius at 3-week high as it aims for recovery in 2024

** Shares in Sartorius  SATG.DE  soar around 9% to
three-week high after the Franco-German lab supplies maker said
it expects its sales revenue and margin to rise in 2024, and
announced new mid-term targets
    ** For 2024, the company forecasts an increase in group
sales revenue in the mid-to-high single-digit percentage range,
and projects average double-digit annual growth through to 2028
    ** It expects underlying EBITDA margin to rise to slightly
more than 30% in 2024, from 28.3% last year
    ** "While the FY 24 sales guidance seems in line with market
expectations, the margin guidance suggests some upside to
estimates," says Michael Heider from Warburg Research
    ** Heider adds that the new mid-term outlook suggests a
return to historic growth rates, which is certainly "positive"
    ** "While the FY 23 numbers are largely in-line and mid-term
outlook implies a low-to-mid single digit cut to consensus, the
stock is likely rising on account of a relief rally," says
Virendra Chauhan from AlphaValue
    ** If gains hold, the stock will see its best day in nearly
three years
        ** Its French unit Sartorius Stedim Biotech  STDM.PA 
jumps 6%
  

 (Reporting by Mateusz Dobrzyniewski)
 ((Mateusz.dobrzyniewski@thomsonreuters.com))

Recent news on Sartorius Stedim Biotech SA

See all news